טוען...
Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential
In humans, passive immunotherapy with anti-CD20 monoclonal antibodies (mAbs) has created immeasurable improvements in outcomes of patients with B-cell malignancies. However, the lack of comparable reagents has precluded development of this approach in dogs. We developed a novel anti-canine CD20 mAb...
שמור ב:
| הוצא לאור ב: | Leuk Lymphoma |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5002357/ https://ncbi.nlm.nih.gov/pubmed/24724777 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2014.914193 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|